For this reason, MR antagonists like eplerenone and spironolactone are a part of the standard approach for managing heart failure with low EF, and are occasionally incorporated into treatment for DMD cardiomyopathy [7]. Here, NR3C2 is linked to Duchenne muscular dystrophy.